PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

ATS 2024 ARDS Guideline Update: Corticosteroids, VV-ECMO, NMBAs and PEEP Strategies Reappraised

ATS ARDS guideline 2024American Thoracic Societyacute respiratory distress syndromecorticosteroidsneuromuscular blocking agentscisatracuriumVV-ECMOPEEPlung recruitment maneuvers Critical Care / ICU

Background Information

New guidelines offer updated strategies for ARDS management.

The guidelines provide updated management strategies for adult patients with acute respiratory distress syndrome (ARDS). Conditional recommendations for corticosteroids, VV-ECMO in selected severe ARDS, neuromuscular blockers in early severe ARDS, and higher PEEP without lung recruitment maneuvers in moderate-to-severe ARDS. These guidelines offer actionable insights for optimizing ARDS treatment in critical care settings, although real-world adaptation may vary. Updated guidelines refine ARDS management with evidence-based recommendations for optimal patient outcomes.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Qadir N, Sahetya S, Munshi L, Summers C, Abrams D, Beitler J, Bellani G, Brower RG, Burry L, Chen JT, Hodgson C, Hough CL, Lamontagne F, Law A, Papazian L, Pham T, Rubin E, Siuba M, Telias I, Patolia S, Chaudhuri D, Walkey A, Rochwerg B, Fan E

Citation: Qadir N, Sahetya S, Munshi L, et al. An Update on Management of Adult Patients with Acute Respiratory Distress Syndrome: An Official American Thoracic Society Clinical Practice Guideline. American journal of respiratory and critical care medicine. 2024;209(1):24-36. doi:10.1164/rccm.202311-2011ST

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.